Literature DB >> 3113330

Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa.

H Giamarellou, G Petrikkos.   

Abstract

In vitro interactions of ciprofloxacin with imipenem and amikacin were evaluated by the killing-curve technique against 26 Pseudomonas aeruginosa strains resistant to amikacin and resistant or moderately susceptible to ciprofloxacin and imipenem. Imipenem enhanced killing by ciprofloxacin in tests with 11 strains, whereas amikacin enhanced killing in tests with only 4 strains.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3113330      PMCID： PMC284223          DOI： 10.1128/AAC.31.6.959

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

Review 2.  The new quinolones and their combinations with other agents for therapy of severe infections.

Authors:  N Desplaces; L Gutmann; J Carlet; J Guibert; J F Acar
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

3.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

4.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Transferrable resistance to tobramycin in Klebsiella pneumoniae and Enterobacter cloacae associated with enzymatic acetylation of tobramycin.

Authors:  B H Minshew; R K Holmes; J P Sanford; C R Baxter
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Authors:  L J Chalkley; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

10.  Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin.

Authors:  L E Bryan; S Kwan
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191
View more
  12 in total

1.  In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.

Authors:  C I Bustamante; R C Wharton; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 2.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram.

Authors:  R B Clark; C B Pakiz; M K Hostetter
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

4.  In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.

Authors:  D Milatovic; C Wallrauch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

5.  Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations.

Authors:  A W Chow; J Wong; K H Bartlett; S D Shafran; H G Stiver
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 7.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

Authors:  E Gradelski; L Valera; D Bonner; J Fung-Tomc
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Interactions of Ceftazidime and Amikacin on Multiresistant Pseudomonas aeruginosa: Have They Altered in the Six-Year Period from 1988 to 1994?

Authors:  E J Giamarellos-Bourboulis; A Pefanis; P Grecka; K Kanellakopoulou; H Giamarellou
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.